The Pharmacy and Poisons Board (PPB) has alerted the public about suspicious batches of falsified and substandard (SF) Truvada product suspected to be circulating within the Kenyan market.
According to to PPB, the product batches in question are TRUVADA 200mg/300mg tablets (Emtricitabine 200mg/Tenofovir Disoproxil 300mg) manufactured by Gilead Sciences Inc.
The products bears the Batch numbers B4033894D and B425875D.
“The public is notified that these product batches are illegally in the market as they have FAILED to meet the approved marketing authorization requirements evidenced by falsified packaging and labelling” said Dr Siyoi, the CEO, PPB.
Consequently, the PPB cautions the public against use of these specific product batches number B4033894D and B425875D as their safety, quality and efficacy cannot be assured.
“The PPB will take stern legal and regulatory action against any person found to be engaged in any form of trading, distribution, wholesale, retail, issuance, or dispensing of these product batches” further warned Dr Siyoi.
Further, in an effort to safeguard public health and safety, the PPB has initiated a rapid response and heightened surveillance to verify whether the SF Truvada product is presently circulating in the Kenyan market.
The PPB assures the public that other batches of this product currently in circulation in the Kenyan market meet the required marketing authorization requirements on safety, quality and efficacy.
“We urge members of the public and healthcare providers to report all suspicious, substandard, and falsified medical products to the Pharmacy and Poisons Board” reiterated Dr Siyoi.
